Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade.
LAG-3
Nanobody
cancer
immune checkpoint
nuclear imaging
single domain antibody
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
20
10
2020
accepted:
03
02
2021
pubmed:
14
3
2021
medline:
6
1
2022
entrez:
13
3
2021
Statut:
ppublish
Résumé
Recent advances in the field of immune-oncology led to the discovery of next-generation immune checkpoints (ICPs). Lymphocyte activation gene-3 (LAG-3), being the most widely studied among them, is being explored as a target for the treatment of cancer patients. Several antagonistic anti-LAG-3 antibodies are being developed and are prime candidates for clinical application. Furthermore, validated therapies targeting cytotoxic T-lymphocyte-associated protein-4, programmed cell-death protein-1, or programmed cell-death ligand-1 showed that only subsets of patients respond. This finding highlights the need for better tools for patient selection and monitoring. The potential of molecular imaging to detect ICPs noninvasively in cancer is supported by several preclinical and clinical studies. Here, we report on a single-domain antibody to evaluate whole-body LAG-3 expression in various syngeneic mouse cancer models using nuclear imaging.
Identifiants
pubmed: 33712537
pii: jnumed.120.258871
doi: 10.2967/jnumed.120.258871
pmc: PMC8612328
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Single-Domain Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1638-1644Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Mol Cancer Ther. 2019 Nov;18(11):2051-2062
pubmed: 31395688
Blood Adv. 2020 Sep 8;4(17):4069-4082
pubmed: 32870971
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Theranostics. 2018 Jun 7;8(13):3559-3570
pubmed: 30026866
Biomolecules. 2020 Sep 29;10(10):
pubmed: 33003481
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374804
J Immunol. 2002 Apr 15;168(8):3874-80
pubmed: 11937541
Biomolecules. 2019 Sep 29;9(10):
pubmed: 31569553
Mol Imaging Biol. 2019 Oct;21(5):898-906
pubmed: 30671739
Eur J Immunol. 2005 Jul;35(7):2081-8
pubmed: 15971272
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
MAbs. 2019 Aug/Sep;11(6):1139-1148
pubmed: 31242068
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
J Gene Med. 2003 Aug;5(8):654-67
pubmed: 12898635
Blood Adv. 2020 Apr 14;4(7):1367-1377
pubmed: 32267932
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
Cancer Res. 2014 Jul 1;74(13):3418-28
pubmed: 24769443
J Nucl Med. 2019 Sep;60(9):1213-1220
pubmed: 30796165
Oncotarget. 2015 Sep 29;6(29):27359-77
pubmed: 26318293
Eur Radiol. 2019 Aug;29(8):4294-4302
pubmed: 30506221
J Nucl Med. 2015 Aug;56(8):1265-71
pubmed: 26069306
J Nucl Med. 2014 Oct;55(10):1678-84
pubmed: 25157043
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Leukemia. 2014 Feb;28(2):444-7
pubmed: 24166214
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Cancer Res. 2019 Aug 15;79(16):4149-4159
pubmed: 31248966
Int J Cancer. 2018 Dec 15;143(12):3201-3208
pubmed: 30248181
Theranostics. 2017 Jul 14;7(11):2924-2939
pubmed: 28824726
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Immunol Lett. 1998 Apr;61(2-3):109-12
pubmed: 9657262
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
J Hematol Oncol. 2018 Dec 21;11(1):142
pubmed: 30577797